The significance of HERC5, IFIH1, SAMD4, SEMA3A and MCTP1 genes expression in resistance to cytotoxic drugs in ovarian cancer cell lines-Reference-Cited by-同舟云学术

The significance of HERC5, IFIH1, SAMD4, SEMA3A and MCTP1 genes expression in resistance to cytotoxic drugs in ovarian cancer cell lines

Published:2021-09-01 Issue:3 Volume:9 Page:138-147
ISSN:2544-3577
Container-title:Medical Journal of Cell Biology
language:en
Short-container-title:

Author:

Nowacka Marta¹,Ginter-Matuszewska Barbara²,Świerczewska Monika¹,Nowicki Michał¹,Zabel Maciej³⁴,Sterzyńska Karolina¹,Januchowski Radosław³

Affiliation:

1. Department of Histology and Embryology , Poznań University of Medical Sciences , Poznań , Poland

2. Department of Infectious Diseases, Hepatology and Acquired Immunodeficiency , Poznań University of Medical Sciences , Poland

3. Department of Anatomy and Histology, Collegium Medicum , University of Zielona Góra , Zielona Góra , Poland

4. Division of Histology and Embryology, Department of Human Morphology and Embryology , Wrocław Medical University , Wrocław , Poland

Abstract

Abstract Resistance to chemotherapy is the main obstacle in contemporary ovarian cancer treatment. The aim of this study was the evaluation of expression of HERC5, IFIH1, SAMD4, MCTP1 and SEMA3A mRNA and assessment their role in resistance to cisplatin, paclitaxel, doxorubicin and topotecan in seven ovarian cancer cell lines. MTT assay was used in resistance assessment. Quantitative polymerase chain reaction was performed to measure the expression levels of the genes. We observed different levels of resistance among cell lines. The resistance was not related to the expression of drug transporters genes. The expression of HERC5 and IFIH1 genes was upregulated, and the expression of SEMA3A gene was downregulated. Expression of SAMD4 was upregulated in PEA1, PEA2, and PEO23 cell lines, and expression of MCTP1 was downregulated in A2780, PEA2, and PEO23 cell lines. Upregulation of HERC5, IFIH1, and SAMD4 and downregulation of SEMA3A and MCTP1 in TOP-resistant ovarian cancer cell lines may suggest some role of those genes in topotecan resistance development.

Publisher

Walter de Gruyter GmbH

Subject

Cell Biology,Molecular Biology

Link

https://www.sciendo.com/pdf/10.2478/acb-2021-0019

Reference50 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34; DOI:10.3322/caac.21551.

2. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14; DOI:10.1016/j.bpobgyn.2016.08.006.

3. Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian cancer. Annals of Oncology. 2017;28:viii51–6; DOI:10.1093/annonc/mdx441.

4. Webber K, Friedlander M. Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:126–138; DOI:10.1016/j.bpobgyn.2016.11.004.

5. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001;478(1–2):23–43; DOI:10.1016/s0027-5107(01)00141-5.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of the Polymorphisms and Expression Levels of the BCL2, BAX and c-MYC Genes in Patients with Ovarian Cancer;International Journal of Molecular Sciences;2023-11-14

2. The TGFBI gene and protein expression in topotecan resistant ovarian cancer cell lines;Advances in Medical Sciences;2023-09